KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1–p38 MAPK hepatic metabolic axis

This study identifies KLF9 as a key transcriptional regulator driving IH-associated MASLD by repressing NR4A1 and inhibiting p38 MAPK signaling, thereby promoting hepatic lipogenesis. Targeting the KLF9-NR4A1 axis may offer a novel therapeutic approach for managing MASLD in patients with OSA and other hypoxia-related disorders.